Cargando…

Real-world use of an etanercept biosimilar including selective versus automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study

OBJECTIVE: Biosimilars are approved as an alternative treatment to their originators. We compared the clinical outcomes of etanercept (ETN) biosimilar compared with ETN originator in real-world practice, from two local health boards in Wales with different policies on switching: automatic vs selecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooksey, Roxanne, Brophy, Sinead, Kennedy, Jonathan, Seaborne, Michael, Choy, Ernest
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336562/ https://www.ncbi.nlm.nih.gov/pubmed/35910710 http://dx.doi.org/10.1093/rap/rkac056

Ejemplares similares

Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK
por: Cooksey, Roxanne, et al.
Publicado: (2021)

Development of data-driven framework for automatically identifying patient cohorts from linked electronic health records
por: Fern'andez-Guti'errez, Fabiola, et al.
Publicado: (2017)

Mining Primary Care Electronic Health Records for Automatic Disease Phenotyping: A Transparent Machine Learning Framework
por: Fernández-Gutiérrez, Fabiola, et al.
Publicado: (2021)

Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality
por: Cooksey, Roxanne, et al.
Publicado: (2022)

Predicting a diagnosis of ankylosing spondylitis using primary care health records–A machine learning approach
por: Kennedy, Jonathan, et al.
Publicado: (2023)

Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK
por: Cooksey, Roxanne, et al.
Publicado: (2020)

Impact of mindfulness for people with arthritis
por: Brophy, Sinead, et al.
Publicado: (2017)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis
por: Zhou, Shang-Ming, et al.
Publicado: (2016)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

The coding of telephone consultations in UK primary care databases: are we picking up all the calls?
por: Atkinson, Mark D, et al.
Publicado: (2023)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
por: Afzali, Anita, et al.
Publicado: (2021)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Healthcare use attributable to COVID-19: a propensity-matched national electronic health records cohort study of 249,390 people in Wales, UK
por: Kennedy , J, et al.
Publicado: (2023)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali(®)) Versus Etanercept (Enbrel(®)) - Findings from a Nurse Survey in Europe
por: Thakur, Kunal, et al.
Publicado: (2016)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
por: Hu, Rui, et al.
Publicado: (2023)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data
por: Cooksey, Roxanne, et al.
Publicado: (2015)

Switching patients with inflammatory arthritis from Etanercept (Enbrel(®)) to the biosimilar drug, SB4 (Benepali(®)): A single-centre retrospective observational study in the UK and a review of the literature
por: Madenidou, Anastasia-Vasiliki, et al.
Publicado: (2019)

Concept libraries for automatic electronic health record based phenotyping: A review
por: Almowil, Zahra A, et al.
Publicado: (2021)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Health checks for adults with intellectual disability and association with survival rates: a linked electronic records matched cohort study in Wales, UK
por: Kennedy, Natasha, et al.
Publicado: (2022)

Mixed-methods evaluation comparing the impact of two different mindfulness approaches on stress, anxiety and depression in school teachers
por: Todd, Charlotte, et al.
Publicado: (2019)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_60otfs5rq28s8iu28qt113nue6